ReviewAdvanced drug delivery reviews2014
Tissue-engineered kidney disease models.
Review in Advanced drug delivery reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 93 citations in OpenAlex.
- CaAntibodies (Basel, Switzerland) · 2026Article
- Microphysiological Systems for Comorbidity Studies: Chronic Kidney Disease and Osteoarthritis.Advanced healthcare materials · 2025Review
- Kidney Organoids: Current Advances and Applications.Life (Basel, Switzerland) · 2025Review
- Key parameters for designing robust 2D and 3D spheroid models forBioengineering & translational medicine · 2025Review
- A Novel Protocol for Culturing Polarized Proximal Tubular Epithelial Cells from Kidney Biopsies: Enhancing Platforms for Drug Excretion and Nephrotoxicity Studies.Journal of xenobiotics · 2025Article
- Recent advances and future directions in urinary system tissue engineering.Materials today. Bio · 2025Review
- Kidney Fibrosis In Vitro and In Vivo Models: Path Toward Physiologically Relevant Humanized Models.Advanced healthcare materials · 2025Review
- Chemical Synthesis and Antifibrotic Properties of (±)-Cochlearol T, (±)-Ganocochlearin A, and (±)-Cochlearol Y.ACS medicinal chemistry letters · 2024Article
- 3D Humanized Bioprinted Tubulointerstitium Model to Emulate Renal Fibrosis In Vitro.Advanced healthcare materials · 2024Article
- Precision nephrotoxicity testing using 3D in vitro models.Cell & bioscience · 2023Review
- Development of an In Vitro Model for Inflammation Mediated Renal Toxicity Using 3D Renal Tubules and Co-Cultured Human Immune Cells.Tissue engineering and regenerative medicine · 2023Article
- Alternative Non-Mammalian Animal and Cellular Methods for the Study of Host-Fungal Interactions.Journal of fungi (Basel, Switzerland) · 2023Review
- Modelling acute myeloid leukemia (AML): What's new? A transition from the classical to the modern.Drug delivery and translational research · 2023Review
- Building Blood Vessel Chips with Enhanced Physiological Relevance.Advanced materials technologies · 2023Article
- Three-dimensional cell culture (3DCC) improves secretion of signaling molecules of mesenchymal stem cells (MSCs).Biotechnology letters · 2022Article
- The complex interplay between kidney injury and inflammation.Clinical kidney journal · 2021Review
- Renal proximal tubular epithelial cells: review of isolation, characterization, and culturing techniques.Molecular biology reports · 2020Review
- Microfluidic lumen-based systems for advancing tubular organ modeling.Chemical Society reviews · 2020Review
- Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug Products.The AAPS journal · 2020Article
- Organ-on-a-chip engineering: Toward bridging the gap between lab and industry.Biomicrofluidics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Renal disease represents a major health problem that often results in end-stage renal failure necessitating dialysis and eventually transplantation. Historically these diseases have been studied with patient observation and screening, animal models, and two-dimensional cell culture. In this review, we focus on recent advances in tissue engineered kidney disease models that have the capacity to compensate for the limitations of traditional modalities. The cells and materials utilized to develop these models are discussed and tissue engineered models of polycystic kidney disease, drug-induced nephrotoxicity, and the glomerulus are examined in detail. The application of these models has the potential to direct future disease treatments and preclinical drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.